Bloom Science treats the brain by treating the gut.

A drug company whose lead drug is alive.

Walk into most biotechs and the product sits in a vial: a small molecule, a sequence of letters, a thing chemists drew. Walk into Bloom Science and the product is bacteria - cultured, dosed, and swallowed once a day.

Bloom Science, Inc. is a clinical-stage company in San Diego with roughly sixteen people and an unusually specific conviction: that some of the body's hardest neurological problems are being managed, badly, by the diet, and that the messenger is the microbiome. Their lead candidate, BL-001, is an oral live biotherapeutic. It is not designed to add a foreign chemical to your bloodstream. It is designed to reproduce, through gut microbes, the same biology that makes the ketogenic diet calm seizures - minus the diet nobody can stick to.

It sounds like a stretch. Most things worth funding do.

The ketogenic diet works. Almost nobody can follow it.

For a century, doctors have watched a strange thing happen to children with drug-resistant epilepsy: put them on a high-fat, near-zero-carb ketogenic diet, and the seizures often quiet down. It is one of the oldest treatments in neurology and one of the most inconvenient. The diet is brutal to maintain, hard on the body over years, and easy to break with a single birthday cake.

So medicine was left with an irritating gap. A known intervention that helps the brain - and a delivery method (the daily refusal of most food) that fails patients in the real world. The mechanism was a mystery, too. Why would what you eat, or don't eat, reach all the way up to a misfiring neuron?

The answer that pulled Bloom into existence came from the gut. Research increasingly pointed to the gut-immune-brain axis: the network of neural, metabolic, hormonal, and immune signals running between your intestines and your head. The ketogenic diet, it turned out, reshapes the microbiome - and the microbiome appears to carry part of the therapeutic message upstream.

Out of a UCLA lab, with a license and a hunch.

The science traces to UCLA, where Elaine Hsiao's lab studied how gut microbes influence the brain. Bloom launched with an exclusive technology license from the university and a founding team willing to wager that you could turn a diet's effect into a manufacturable medicine.

Christopher Reyes, Ph.D., runs the company as CEO and founder. Louis Licamele, Ph.D. - whose background is in clinical and data science - joined the founding executive team as Chief Development Officer, the person responsible for turning microbiome hypotheses into actual trials with actual endpoints. Co-founders Elaine Hsiao and Raphael Valdivia anchor the science from the advisory side.

The bet was not "the microbiome is interesting." Everyone in 2017 thought the microbiome was interesting; it was the kale of biotech. The bet was narrower and harder: that you could identify which specific microbes and functions reproduce a clinical benefit, and then build a drug around them.

IrisRx works backwards. BL-001 is the result.

Most drug discovery runs forward: pick a target, screen a million compounds, hope one hits. Bloom's IrisRx platform runs the other direction. It starts from an intervention already proven to work in patients - the ketogenic diet - and reverse-translates it, decoding the compositional and functional microbiome building blocks responsible for the effect. Then it designs multi-pathway therapeutics from gut commensal microbes and synthetic biology.

Out of that comes BL-001: a first-in-class, orally delivered, once-daily live biotherapeutic product built to replicate the therapeutic effects of ketogenic biology as a scalable, pharmaceutical-grade therapy. Same biology as the diet. None of the deprivation.

Three programs, one organism. The unusual part isn't the breadth - it's that they all run off the same live drug.

Microbiome hype is cheap. Endpoints aren't.

The microbiome field has a credibility problem, and Bloom knows it. For a decade the space promised cures for everything and delivered mostly press releases. The way out is unglamorous: run real studies, report real numbers.

Bloom's Phase 1 work on BL-001 reported what an early trial is supposed to - that the drug is safe and tolerable - and added something a placebo doesn't usually produce: statistically significant weight loss. It's early. It's one read. But it's a number, not a narrative.

A small team, a single live asset, a focused raise. In biotech, narrowness is a feature - the graveyard is full of platforms that chased everything.

Revolutionizing metabolic and neurological health.

Bloom's stated aim is to unlock new therapeutic pathways for metabolic and neurological health by harnessing the gut-immune-brain axis. Stripped of the slogan, it means this: take interventions we already know help the brain and body, figure out how the microbiome carries them, and deliver that as a medicine people can actually take.

The target list is deliberately heavy - Dravet syndrome, obesity, ALS, neurodegeneration. These are conditions where existing options are thin and the patients are waiting. A patient-advocacy director sits on the leadership team, which tells you something about who Bloom thinks it answers to.

Back to the vial.

Return to where we started. Most drug companies hold up a vial of chemistry. Bloom Science holds up a capsule of living bacteria and says: this is the medicine.

If the bet pays off, the line between "what you eat" and "what your doctor prescribes" gets blurrier in a useful way. A child with Dravet syndrome wouldn't need a diet that's impossible to keep. An adult managing weight wouldn't need to white-knuckle every meal. The benefit would arrive once a day, in a capsule, carried by microbes doing the work the diet used to demand.

That's still a hypothesis with a long road of trials ahead. But it's a sharper hypothesis than the field usually offers, backed by a real raise, a focused asset, and early numbers that moved. The vial in Bloom's hand is doing something the others can't: it's alive, and it's pointed at the brain.